Ionis Pharmaceuticals IONS
Ionis has three approved drugs and two fresh Phase 3 wins, but the hepatitis B functional-cure PDUFA is the single event that rerates the stock
- Bepirovirsen FiledChronic Hepatitis B · HBV antisense oligonucleotide
$17.1B of 2025 infectious disease blockbuster sales lose US exclusivity by 2037, led by Biktarvy, Descovy. These 3 public biotechs have 3 infectious disease treatments in Phase 3 or filed with the FDA, 2 of them already filed.
2025 sales each company reports from tracked infectious disease treatments losing US exclusivity by 2037. Big pharma has spent $9.2B on 1 infectious disease acquisitions since 2023. See the deals →
Ionis has three approved drugs and two fresh Phase 3 wins, but the hepatitis B functional-cure PDUFA is the single event that rerates the stock
Phase 3-backed SSI drug racing an approval decision against a thin cash cushion, with Azurity's commercialization deal as the bridge
LIBERTY Phase 3 met all endpoints, but a going-concern company must now finance a BLA and approval before cash runs out
Filed treatments are listed first. This shows where late-stage treatments are being developed, not which companies will be acquired. Pipeline data and summaries from Readouts as of 29 September 2026; companies already acquired are left out.
Other areas: Oncology · Immunology · Cardiometabolic · Vaccine · Neuroscience · Other areas